Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Concepts of Graph Theory Applied to the Human Microbiome (GRAHAM)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: United Kingdom
Call: Individual Fellowships (H2020-MSCA-IF-2017, 2017)
Start date: 2018-11-01
End date: 2020-12-01
Duration (months): 24.0
Total project cost (EUR): 195454.8
EU funding (EUR): 195454.8
Participants: 1
Project status: CLOSED

Incidents of cancer, respiratory, and circulatory disease are the highest causes of death among members of the European Union (EU). Elements of these diseases have been linked to the human microbiota, the complex ecosystem of microorganisms which live on and in the human body. Understanding the disruptions to the human microbiota which cause disease is important in furthering our knowledge of these diseases. Although advances in sequencing technology have allowed the exploration of "who" is present in these communities, we still do not have a proper understanding of "what" is present in terms of genetic elements (genomes, operons, genes, and single nucleotide polymorphisms (SNPs)) due to a lack of computaional tools. In GRAHAM, I propose to apply network analysis to the study of disruptions to the human microbiota in order to develop tools and answer questions related to human health and disease. Under this research programme, I will model interactions between genetic elements in publicly available metagenomic datasets of the human microbiota using networks. My background in metagenomic sequencing technologies will be combined with the excellence of a research environment and supervisor rich in experience with applications of network analyses. Deliverables will include open-source software packages, and results of this research will be disseminated via publications, conferences, workshops, and public seminars.

Keywords: human microbiome,metagenomics,gene networks
Harnessing dendritic cell reprogramming for cancer immunotherapy (TrojanDC)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Prevention, Diagnosis and Treatment of Human Diseases
Panel description: Medical technologies and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions, pharmacology, preventative medicine, epidemiology and public health, digital medicine
Countries involved: Sweden
Call: ERC Consolidator Grant (ERC-2019-COG, 2019)
Start date: 2020-10-01
End date: 2025-09-30
Duration (months): 60.0
Total project cost (EUR): 1999835.0
EU funding (EUR): 1999835.0
Participants: 1
Project status: SIGNED

An important hallmark of cancer is the ability to evade the immune system. Genetic mutations in tumor cells result in the accumulation of tumor antigens (TAs), however, increased cell heterogeneity, downregulation of antigen presentation or inhibition of immune cell infiltration allows immune surveillance evasion. For the first time, direct cell reprogramming offers exciting opportunities to overcome these challenges. My group has recently identified a combination of transcription factors (TFs) sufficient to reprogram mouse fibroblasts into antigen-presenting dendritic cells (DCs), providing a new strategy to set in motion antigen-specific immune responses. I hypothesize that a similar combination reprograms tumor cells into antigen presenting cells (APCs). This proposal aims to test a cancer immunotherapy concept based on DC reprogramming and endowed APC function in tumor cells. The work will proceed in three steps. First, I will define optimal TF combinations and external cues to efficiently reprogram human fibroblasts into DCs employing an innovative single-cell screen. Then, I will reprogram mouse and human tumor cells into tumor-APCs followed by characterization of transcriptome, chromatin accessibility, surface peptidome and ability to present antigens to T cells. Finally, I will test whether reprogrammed cells mount an attack against tumors in mouse models. I will further test the hypothesis that intratumoral delivery of reprogramming factors elicits in vivo antigen presentation, immune cell recruitment and tumor regression. The approach proposed here will combine DCs’ antigen processing and presenting abilities with the endogenous generation of TAs. The induction of DC identity in cancer cells with ability to present a constellation of TAs will open new research and therapeutic avenues. This project represents a pioneering contribution by merging cell reprogramming and cancer immunotherapy, paving the way for an entirely new approach to cancer gene therapy.

Keywords: cellular reprogramming,cell fate engineering,dendritic cell,transcription factor,cancer gene therapy,immune evasion,antigen presentation,regenerative medicine,immunology,cancer immunotherapy
Mapping mobility – pathways, institutions and structural effects of youth mobility in Europe (MOVE)

Framework: Horizon 2020 — Societal Challenges
Programme: Europe in a changing world - inclusive, innovative and reflective societies
Action type: Research and Innovation actions
Countries involved: Germany,Spain,Germany,Germany,Norway,Hungary,Romania,Luxembourg
Call: Youth mobility: opportunities, impacts, policies (H2020-YOUNG-SOCIETY-2014, 2014)
Start date: 2015-05-01
End date: 2018-04-30
Duration (months): 36.0
Total project cost (EUR): 2499910.0
EU funding (EUR): 2499910.0
Participants: 10
Project status: CLOSED

The overall ambition of MOVE is to provide a research-informed contribution towards an improvement of the conditions of the mobility of young people in Europe and a reduction of the negative impacts of mobility through the identification of ways of good practice thus fostering sustainable development and wellbeing. The consortium of MOVE is built up of nine partners within six countries: Luxembourg, Germany, Hungary, Norway, Romania and Spain. The main research question is: How can the mobility of young people be ‘good’ both for socio-economic development and for individual development of young people, and what are the factors that foster/hinder such beneficial mobility? Based on an interdisciplinary and multilevel research approach the main objectives of MOVE are to: [1] carry out a comprehensive analysis of the phenomenon of mobility of young people in the EU; [2] generate systematic data about young people’s mobility patterns in Europe based on qualitative case studies, a mobility survey and on secondary data analysis; [3] provide a quantitative integrated database on European youth mobility; [4] offer a data based theoretical framework in which mobility can be reflected, thus contributing to the scientific and political debates. [5] explore factors that foster and factors that hinder good practice based on an integrative approach with qualitative and quantitative evidence. [6] provide evidence-based knowledge and recommendations for policy makers through the development of good-practice models. MOVE is based on a multilevel research design, including case studies on six types of mobility (higher education, voluntary work, employment, vocational training, pupil's exchange and entrepreneurship), a survey (N=6400) and secondary data analysis, taking into consideration social inequality (e.g. migration background, gender, educational inequalities, impairments). The focus will be on the regional contexts of mobility and the agency of young people.

Keywords: mobility,young people,employment,lifelong learning,socioeconomic effects of migration and mobility,student mobility,volunteering
Cooperative ITS for Mobility in European Cities (CIMEC)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Action type: Coordination and support actions
Countries involved: Germany,Spain,Germany,Norway,Belgium,Norway,United Kingdom,United Kingdom
Call: Cooperative ITS for safe, congestion-free and sustainable mobility (H2020-MG-2014_SingleStage_B, 2014)
Start date: 2015-06-01
End date: 2017-05-31
Duration (months): 24.0
Total project cost (EUR): 999962.5
EU funding (EUR): 999961.0
Participants: 8
Project status: CLOSED

Call topic MG3.5-2014 notes that the deployment of C-ITS has not kept pace with the technological development, implying that deployment is being restrained by non-technical factors. CIMEC, as a proposed CSA for this topic, aims to support the accelerated take-up of C-ITS by increasing the alignment of technological solutions with user needs, thereby removing perceived barriers and risks in deployment. European highways authorities are relatively well educated, prepared and supported regarding C-ITS, including through a series of EC- and national funded R&D projects. However the greatest benefits are expected through the more complex and fragmented city context, which up to now is much less understood. CIMEC focuses especially on this urban C-ITS context. CIMEC brings together key collaborative institutions, supported by a panel of core cities and by the European city network Polis. This meta-network has extensive experience in bringing together cities and suppliers to optimise ITS, and has specific expertise in a range of C-ITS at national and European level. The objectives of CIMEC are to •capture and document a set of realistic use cases for C-ITS in cities, supported by robust business cases •identify practical project structures which enable the deployment of these use cases •identify how emerging standards for C-ITS will affect, and should respond to, urban systems and processes •show possible system architecture and workflow of C-ITS support systems •promote multi-sector stakeholder dialogue, engagement and collaboration The principal output will be a roadmap for city deployment of C-ITS which has been validated against user needs and technology maturity, captured in meaningful project descriptions. By developing a single, coherent narrative and communicating it effectively to all relevant stakeholder groups, this will ensure that standards, product development, project management, and policy goals are fully aligned across the European urban C-ITS context.

Keywords: cooperative its,deployment
Roles of spastic paraplegia proteins in organisation of axonal endoplasmic reticulum (ParaplegiaERDros)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: United Kingdom
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2014, 2014)
Start date: 2016-01-01
End date: 2017-12-31
Duration (months): 24.0
Total project cost (EUR): 195454.8
EU funding (EUR): 195454.8
Participants: 1
Project status: CLOSED

Axonal endoplasmic reticulum (ER) is a poorly characterised compartment that is mainly tubular, smooth, and forms a network for long distances along axons. Many mutations for the motor axon degeneration disease, hereditary spastic paraplegia (HSP), affect proteins that model ER shape. The Fellow will test the model that these proteins help form axonal ER, which is disrupted when these proteins are mutated. The time for this is opportune; the host lab has developed tools to detect impaired axon ER organisation in Drosophila; and new HSP genes, some encoding ER proteins of unknown function, are being identified continuously in human patients. To identify proteins involved in its formation, the Fellow will test ER-localized HSP gene products, both singly and in multiply mutant genotypes, for roles in ER organisation in larval motor axons. She will also test whether similar defects appear in long motor and sensory axons in live adults as they age. Finally she will test the effects of HSP protein loss on the finer structure of ER and its association with mitochondria. Through this work the Fellow will help pioneer characterisation of a poorly understood but important cell compartment: how it is formed and some effects of disrupting it. Along with the broader research and training environment, this will help her to develop a profile for her own work in this area.

Keywords: drosophila,endoplasmic reticulum,axons,hereditary spastic paraplegia
Commercial feasibility of a kit for the identification of epigenetic markers in farmed fish (EPIMARK)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Panel: Biotechnology and Biosystems Engineering
Panel description: Biotechnology using all organisms, biotechnology for environment and food applications, applied plant and animal sciences, bioengineering and synthetic biology, biomass and biofuels, biohazards
Countries involved: Norway
Call: ERC Proof of Concept Grant (ERC-2018-PoC, 2018)
Start date: 2018-09-01
End date: 2020-02-29
Duration (months): 18.0
Total project cost (EUR): 149202.5
EU funding (EUR): 149202.5
Participants: 1
Project status: CLOSED

Domestication and selective breeding of the major commercial fish species are essential to enable sustainability of the rapidly expanding aquaculture sector. The existing improvement programmes are based exclusively on genetic markers, overlooking the fact that selection for complex traits is strongly affected by environmental conditions and that epigenetics likely account for a large proportion of the observed phenotypic variation. Non-coding RNAs (e.g., miRNAs) and cytosine methylation (5mC) and hydroxymethylation (5hmC) of DNA are key mechanisms underlying epigenetic regulation of gene expression. We have recently identified a panel of 5mCs, 5hmCs and miRNAs that are potential epigenetic markers (epimarkers) of improved growth in Nile tilapia (Oreochromis niloticus). EPIMARK will evaluate the commercial feasibility of our novel kit of growth epimarkers, so that they can be applied in selective breeding programmes. This will be achieved by (i) validating the miRNA, 5mC and 5hmC epimarkers, (ii) developing an assay for their quantification, (iii) investigating the commercial and financial feasibility and (iv) developing the optimal business strategy, consolidated in a business plan. The EPIMARK kit will lead to a more efficient selection of fish in breeding programs based on growth potential, thereby increasing the profitability and sustainability of the aquaculture industry. The technology developed in EPIMARK will also open important avenues of innovation, including the use of epimarkers for selection of other superior production traits and disease resistance in Nile tilapia and in other species of commercial importance.

Keywords: epigenetic markers,growth,farmed fish,nile tilapia,atlantic salmon
Durable, Environmentally Friendly and High-quality Leather Alternative (EcoLeather)

Framework: Horizon 2020 — Societal Challenges
Programme: Climate action, environment,  resource efficiency and raw materials
Action type: SME instrument
Countries involved: Italy
Call: Boosting the potential of small businesses in the areas of climate action, environment, resource efficiency and raw materials (H2020-SMEINST-1-2016-2017, 2017)
Start date: 2017-08-01
End date: 2017-11-30
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: TERMINATED

Materiko is an Italian company specialising in the manufacture of revolutionary artificial high quality textiles. Due to the flexibility, and high-quality afforded by genuine leather, compared to conventional textiles, it has been used for centuries as material in several industries. However, leather is prone to scratching, water damage and UV damage which can limit its uses, particularly in external applications. Furthermore, the way in which leather is produced presents a huge environmental problem. The tanning process for genuine leather uses on average 360 L of water per m2 and over 50 L of that needs to be processing by wastewater treatment plants for chromium waste considered to be hugely toxic by the EU. To alleviate these environmental problems as well as consumer movement towards non-animal origin products a range of artificial leathers have been developed such as PVC and polyurethane (PU) based faux leathers and natural plant based options. PVC and PU based artificial leather have their own environmental problems including similarly high water usage, use of toxic chemicals and poor recyclability. Both plastic based and plant based leather alternatives have durability and quality issues when replicating genuine leather. The need for a high-quality, more durable, weather-proof leather like material which eliminates animal cruelty, water usage and toxic wastage associated with the genuine leather industry is clear and one for which Materiko have developed an innovative solution. Our EcoLeather is a novel material manufactured using an innovative semi-automatic manufacturing technique which produces a water and chemical free leather alternative which improves upon the physical properties of genuine, such as durability, scratch and weather resistance. With the high-end leather goods market worth an estimated €45 bn globally there is a huge demand for a leather alternative with improved physical properties.

Keywords: leather,eco friendly,polyurethane,resin,spray layering,luxury,textile,durable,uv resistance,scratch resistance,waterproof,fire resistance
Electronic Neuropharmacology (e-NeuroPharma)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Synthetic Chemistry and Materials
Panel description: New materials and new synthetic approaches, structure-properties relations, solid state chemistry, molecular architecture, organic chemistry
Countries involved: Sweden
Call: ERC Advanced Grant (ERC-2018-ADG, 2018)
Start date: 2019-09-01
End date: 2025-02-28
Duration (months): 66.0
Total project cost (EUR): 3237335.0
EU funding (EUR): 3237335.0
Participants: 1
Project status: SIGNED

As the population ages, neurodegenerative diseases (ND) will have a devastating impact on individuals and society. Despite enormous research efforts there is still no cure for these diseases, only care! The origin of ND is hugely complex, spanning from the molecular level to systemic processes, causing malfunctioning of signalling in the central nervous system (CNS). This signalling includes the coupled processing of biochemical and electrical signals, however current approaches for symptomatic- and disease modifying treatments are all based on biochemical approaches, alone. Organic bioelectronics has arisen as a promising technology providing signal translation, as sensors and modulators, across the biology-technology interface; especially, it has proven unique in neuronal applications. There is great opportunity with organic bioelectronics since it can complement biochemical pharmacology to enable a twinned electric-biochemical therapy for ND and neurological disorders. However, this technology is traditionally manufactured on stand-alone substrates. Even though organic bioelectronics has been manufactured on flexible and soft carriers in the past, current technology consume space and volume, that when applied to CNS, rule out close proximity and amalgamation between the bioelectronics technology and CNS components – features that are needed in order to reach high therapeutic efficacy. e-NeuroPharma includes development of innovative organic bioelectronics, that can be in-vivo-manufactured within the brain. The overall aim is to evaluate and develop electrodes, delivery devices and sensors that enable a twinned biochemical-electric therapy approach to combat ND and other neurological disorders. e-NeuroPharma will focus on the development of materials that can cross the blood-brain-barrier, that self-organize and -polymerize along CNS components, and that record and regulate relevant electrical, electrochemical and physical parameters relevant to ND and disorders

Keywords: organic electronics,organic bioelectronics
Evidence-based co-creation methodology for bridging the implementation gap between knowledge and action in health promotion. (Health CASCADE)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Innovative Training Networks (ITN)-European Training Networks
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany,Spain,Sweden,Greece,Belgium,Netherlands,United Kingdom
Call: Innovative Training Networks (H2020-MSCA-ITN-2020, 2020)
Start date: 2021-01-01
End date: 2024-12-31
Duration (months): 48.0
Total project cost (EUR): 4058108.64
EU funding (EUR): 4058108.64
Participants: 7
Project status: SIGNED

- Health CASCADE is an ETN at the intersection of health promotion, public health, social sciences and digital technologies and high impact applications in the health care, occupational, educational and public health sectors. - Scientific basis: Co-creation of health promotion interventions pioneered in Europe. - Aim: To CASCADE co-creation skills and expertise by training of a new generation of professionals capable of working across disciplines, public and private sectors (i) training by doing through ESR research projects; (ii) workshops and tailored courses in science and transferable skills, hands-on experience with an emphasis on collaborative learning and working; (iii) researcher mobility within a wide ranging network of expertise and exposure to a wide variety of research environments - A coordinated effort by 7 beneficiaries and 14 partner organisations from 8 European countries (Belgium, France, Germany, Greece, The Netherlands, Scotland, Spain, Sweden) secures a pan-European multidisciplinary approach in multi-environment (universities, research centres, SMEs, large civil organisations and companies) and -sectoral (education, industry, health care) contexts. - Four high impact fields key for European public health: Education, Workplace, Health Care and Community.

Keywords: participatory,cocreation,co creation,intervention,implementation,translation